Sloučenina obecného vzorce I nebo její soli nebo solváty, kde: m je 1 nebo 2; n je 1 nebo 2; X znamená CH nebo N; Y je vybrán ze skupiny zahrnující vodík, halogen, kyan, CF.sub.3.n., alkyl nebo alkoxy skupinu; R.sup.1.n., který může být v jakékoliv pozici nasyceného kruhového systému, znamená vodík nebo až dva substituenty, které mohou být stejné nebo různé a každý z nich je vybrán ze skupiny zahrnující fluor a C.sub.1-6.n.alkyl; R.sup.2.n. znamená vodík nebo až čtyři substituenty vybrané ze skupiny zahrnující halogen, NO.sub.2.n., CN, N.sub.3.n., CF.sub.3.n.O-, CF.sub.3.n.S-, CF.sub.3.n.CO-, C.sub.1-6.n.alkyl, C.sub.1-6.n.alkenyl, C.sub.1-6.n.alkinyl, C.sub.1-6.n.perfluoralkyl, C.sub.3-6.n.cykloalkyl, C.sub.3-6.n.cykloalkyl-C.sub.1-4.n.alkyl, (C.sub.1-6.n.alkyl)O-, (C.sub.1-6.n.alkyl)CO-, (C.sub.3-6.n.cykloalkyl)O-, (C.sub.3-6.n.cykloalkyl)CO-, (C.sub.3-6.n.cykloalkylC.sub.1-4.n.alkyl)O-, (C.sub.3-6.n.cykloalkylC.sub.1-4.n.alkyl)CO-, fenyl, fenoxy, benzyloxy, benzoyl, fenyl-C.sub.1-4.n.alkyl, (C.sub.1-6.n.alkyl)S-, (C.sub.1-6.n.alkyl)SO.sub.2.n.-, (C.sub.1-4.n.alkyl).sub.2.n.NSO.sub.2.n.-, (C.sub.1-4.n.alkyl).sub.2.n.NSO.sub.2.n.-, (C.sub.1-4.n.alkyl)NHSO.sub.2.n.-, (C.sub.1-4.n.alkyl).sub.2.n.NCO-, oxazolyl, (C.sub.1-4.n.alkyl)NHCO-, CONH.sub.2.n.; nebo R.sup.4.n.CONH- nebo -NR.sup.4.n.R.sup.5.n.; kde R.sup.4 .n.znamená vodík nebo C.sub.1-4.n.alkyl; a R.sup.5 .n.znamená vodík, C.sub.1-4.n.alkyl, formyl, -CO.sub.2.n.C.sub.1-4.n.alkyl nebo -COC.sub.1-4.n.alkyl; pro léčbu epilepsie, migrény a jiných onemocnění.ŕ
Output: In the present invention, there is disclosed a compound of the general formula I or salts or solvates thereof, in which: m is 1 or 2; n is 1 or 2; X represents  CH or N; Y is selected form the group comprising hydrogen, halogen, cyano, CFi3 alkyl or alkoxy group, Re1, which may be at any position within the saturated ring system, denotes hydrogen or up to two substituents which may be the same or different and each of which is selected from the group consisting of fluoro and alkyl having 1 to 6 carbon atoms; Re2 represents hydrogen or up to four substituents selected from the group comprising halogen, NOi2, CN, Ni3, CFi3O-, CFi3S-, CFi3CO-, alkyl having 1 to 6 carbon atoms, alkenyl containing 1 to 6 carbon atoms, alkynyl containing 1 to 6 carbon atoms, perfluoroalkyl having 1 to 6 carbon atoms, cycloalkyl containing 3 to 6 carbon atoms, cycloalkylalkyl  containing 3 to 6 carbon atoms in the cycloalkyl moiety and 1 to 4 carbon atoms in the alkyl moiety, alkylO- containing 1 to 6 carbon atoms, alkylCO- containing 1 to 6 carbon atoms in the alkyl moiety, cycloalkylO- containing 3 to 6 carbon atoms, cycloalkylCO- containing 3 to 6 carbon atoms in the alkyl moiety, cycloalkylalkylO- containing 3 to 6 carbon atoms in the cycloalkyl moiety and 1 to 4 carbon atoms in the alkyl moiety, cycloalkylalkylCO- containing 3 to 6 carbon atoms in the cycloalkyl moiety and 1 to 4 carbon atoms in the alkyl moiety, phenyl, phenoxy, benzyloxy, benzoyl, phenylalkyl- containing 1 to 4 carbon atoms in the alkyl moiety, alkylS- having 1 to 6 carbon atoms in the alkyl moiety, alkylSOi2- containing 1 to 6 carbon atoms in the alkyl moiety, alkyli2NSOi2- containing 1 to 4 carbon atoms in the alkyl moiety, alkylNHSOi2- containing 1 to 4 carbon atoms in the alkyl moiety, alkyli2NCO- containing 1 to 4 carbon atoms in the alkyl moiety, oxazolyl, alkylNHCO- containing 1 to 4 carbon atoms in the alkyl moiety, CONHi2; or Re4CONH- or -NRe4Re5, wherein Re4 represents hydrogen or alkyl having 1 to 4 carbon atoms; and Re5 denotes hydrogen, alkyl having 1 to 4 carbon atoms, formyl, -COi2alkyl having 1 to 4 carbon atoms in the alkyl moiety or ûCOCalkyl having 1 to 4 carbon atoms in the alkyl moiety. The above-described compound is indicated to be useful in the treatment and prophylaxis of epilepsy, migraine, and other disorders.